Paris-based Gleamer, which develops AI software for radiologists, including its FDA-cleared BoneView, raised a €27M Series B, taking its total funding to €36M
Paul Sawers / TechCrunch :
Context & Ripple Effects
Gleamer's €27M Series B lands in a crowded but well-funded lane: radiology AI startups on both sides of the Atlantic have been pulling in eight-figure rounds, from Exo's $40M raise for AI workflow software and portable ultrasound through Medivis's $20M Series A for holographic MRI and CT rendering just weeks earlier. What distinguishes Gleamer is that its flagship BoneView is already FDA-cleared — it is selling into clinical workflows, not promising future ones.
The round also matters for geography. With Paris positioning itself against London as Europe's top AI hub, Gleamer joins Marseille-based Volta Medical, which raised a €36M Series B for surgical AI as evidence that French medical-AI companies can raise at US-adjacent scale, even if totals like Gleamer's €36M still trail US peers such as Rad AI, whose $50M Series B took it past $80M raised.
First-order effects
- Gleamer gets the capital to push BoneView beyond its FDA-cleared bone-fracture reading niche and expand its radiologist software suite, while its €36M total keeps it in the game against better-capitalized US rivals like Rad AI.
Second-order effects
- Competitors in the radiology-AI funding race — Rad AI on reporting, Medivis on surgical visualization, Cleerly on cardiac imaging — now face pressure to show clinical validation, since FDA clearance is emerging as the differentiator investors reward with Series B-scale checks.
Third-order effects
- If the pattern holds, radiology AI consolidates around cleared, workflow-embedded platforms, with European players like Gleamer competing not on capital raised but on regulatory approvals and integration depth — and the FDA's clearance pipeline becoming the de facto gate that decides which vendors survive.
The trend: Venture capital is consolidating around clinically validated, FDA-cleared radiology AI, with Paris emerging as a European counterweight to the US funding centers.